Louise Chen
Stock Analyst at Scotiabank
(2.18)
# 2,547
Out of 4,814 analysts
298
Total ratings
36.65%
Success rate
-5.6%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $13.41 | +4.44% | 2 | Apr 3, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $105 → $80 | $53.79 | +48.73% | 2 | Mar 20, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.79 | +570.39% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $18.27 | +201.04% | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Initiates: Sector Outperform | $150 | $84.69 | +77.12% | 1 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $47.45 | +15.91% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $1.92 | +683.29% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $24.24 | +106.27% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $4.81 | +211.85% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $4.34 | +291.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $26.67 | +162.47% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $8.18 | +511.62% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $14.88 | +101.61% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $1.13 | +1,227.43% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $28.86 | +90.58% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.78 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $58.08 | +175.48% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $30.50 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $22.15 | +103.21% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $157.44 | +36.56% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.16 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $77.98 | +98.77% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.14 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $839.90 | +5.37% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.80 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.15 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.70 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.09 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.44 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $173.00 | +15.61% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.62 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.90 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.24 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.08 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $563.16 | +64.25% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.90 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $6.33 | +926.86% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.77 | +549.35% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $0.85 | +2,841.18% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.74 | +263.90% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.01 | +284.32% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.00 | +400.00% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.87 | +381.28% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $5.47 | +30,849,991.41% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $428.32 | -39.76% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $13.64 | +10.01% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.84 | +2,624.80% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.43 | +1,303.51% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.21 | +624.64% | 1 | Jun 22, 2017 |
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $13.41
Upside: +4.44%
Sarepta Therapeutics
Mar 20, 2025
Maintains: Sector Perform
Price Target: $105 → $80
Current: $53.79
Upside: +48.73%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.79
Upside: +570.39%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.27
Upside: +201.04%
Blueprint Medicines
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $150
Current: $84.69
Upside: +77.12%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $47.45
Upside: +15.91%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $1.92
Upside: +683.29%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $24.24
Upside: +106.27%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.81
Upside: +211.85%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $4.34
Upside: +291.71%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $26.67
Upside: +162.47%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $8.18
Upside: +511.62%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $14.88
Upside: +101.61%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $1.13
Upside: +1,227.43%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $28.86
Upside: +90.58%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.78
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $58.08
Upside: +175.48%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.50
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $22.15
Upside: +103.21%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $157.44
Upside: +36.56%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.16
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $77.98
Upside: +98.77%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.14
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $839.90
Upside: +5.37%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.15
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.70
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.09
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.44
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $173.00
Upside: +15.61%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.62
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.90
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.24
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.08
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $563.16
Upside: +64.25%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.90
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $6.33
Upside: +926.86%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $0.77
Upside: +549.35%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $0.85
Upside: +2,841.18%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.74
Upside: +263.90%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.01
Upside: +284.32%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.00
Upside: +400.00%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.87
Upside: +381.28%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $5.47
Upside: +30,849,991.41%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $428.32
Upside: -39.76%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $13.64
Upside: +10.01%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.84
Upside: +2,624.80%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.43
Upside: +1,303.51%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.21
Upside: +624.64%